Alfacyte.co.uk Login
Searching for the Alfacyte.co.uk login page? Here you will find the most up-to-date links to login pages related to alfacyte.co.uk. Also, we have collected additional information about alfacyte.co.uk login for you below.
| Category | A |
|---|---|
| Domain name | alfacyte.co.uk |
| IP | 94.136.40.51 |
| Country by IP | GB |
| Country by HTML code | GB |
| Web server type | Nginx |
Home - ILC Therapeutics Ltd Hybrid interferon pioneer
We have an active pipeline of hybrid interferons, and currently our lead candidate is a broad-spectrum antiviral drug known as Alfacyte™. Opportunities exist to exploit the technology platform to make a significant impact on virological conditions such as COVID-19, respiratory syncytial virus (RSV), HIV and herpes, and in the fields of oncology, dermatology, and neurology … Visit website
Alfacyte raises Seed Investment to move from research into …
Alfacyte also received £100,000 from Scottish Enterprise’s SMART:SCOTLAND grant programme to directly fund development and production of the proprietary molecule that will form the basis of the vaccine. Prof. Bill Stimson, Alfacyte’s Chief Scientific Officer, said “Peanut allergy affects up to 2% of the Western population and is the most ... Visit website
ILC Therapeutics’ Alfacyte proves effective against SARS-CoV-2
Alfacyte is designed to help accelerate this response and prevent disease progression. And now independent research at the University of St Andrews led by Dr. Catherine Adamson, a specialist in viral diseases, has demonstrated the superior effectiveness of Alfacyte in vitro against SARS-CoV-2. Visit website
Pharma firm Alfacyte secures £250,000 in funding round
BioCity Scotland-based pharmaceutical outfit Alfacyte has received a fresh £250,000 injection to advance development of a topical treatment for psoriasis. News you can trust since 1817. Visit website
Interferon alpha hybrid - Alfacyte - AdisInsight
Interferon alpha hybrid - Alfacyte Latest Information Update: 28 Jun 2021. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in our drug ... Visit website
Biotech firm ILC Therapeutics partners with
Lanarkshire-based biotech firm ILC Therapeutics has announced a research partnership with the University of St Andrews to work on a drug which could save the lives of Covid-19 patients.. Scientists at ILC believe Alfacyte could be more effective than other drugs in preventing Covid-19 induced acute respiratory distress syndrome (ARDS). Visit website
News - ILC Therapeutics Ltd
ILC Therapeutics strengthens team to accelerate development of COVID-19 drug. March 17, 2022. Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials of COVID-19 drug. Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon ... Visit website
Alfacyte - Funding, Financials, Valuation & Investors
Alfacyte is developing many therapeutic application to use in Autoimmune disease, Cancer immunotherapy and Food allergy. Visit website
ALFACYTE Trademark of ILC Therapeutics Limited. Serial …
ALFACYTE is a trademark and brand of ILC Therapeutics Limited, , GB . This trademark was filed to USPTO on Thursday, September 16, 2021. The ALFACYTE is under the trademark classification: Pharmaceutical Products; The ALFACYTE trademark covers Sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food … Visit website
Alfacyte Ltd. - Company Profiles - BCIQ
For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the … Visit website
ALFACYTE Trademark of ILC Therapeutics Limited - Serial …
On Thursday, September 16, 2021, a trademark application was filed for ALFACYTE with the United States Patent and Trademark Office. The USPTO has given the ALFACYTE trademark a serial number of 79327654. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, December 9, 2021. Visit website
ALFACYTE Trademark Application of ILC Therapeutics Limited
Filed in September 16 (2021), the ALFACYTE covers Sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for ... Visit website
Alfacyte Ltd Company Profile, Financial and Strategic SWOT …
Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy. The company was founded in 2012 and is based in Glasgow, United Kingdom. digitGaps report on … Visit website
ALFACYTE LTD., Patent Owner, MILNGAVIE GLASGOW, GB
View ALFACYTE LTD.s, MILNGAVIE GLASGOW, GB, patent portfolio profile on Patent Buddy. Patent Buddy is the worlds most extensive database and networking website for patent attorneys, agents and inventors helping inventors like ALFACYTE LTD. showcase inventions and connect to patent attorneys, patent agents, law firms, corporations, universities, and government agencies … Visit website
Alfacyte moves into critical development phase
Published Jul 30, 2015. + Follow. Glasgow based pharmaceutical company Alfacyte announced today it has raised £350,000 in equity and grant funding to advance development of an oral vaccine for ... Visit website
ILC THERAPEUTICS LTD (SC426667) - UK Business Directory
Company Number: SC426667 ILC THERAPEUTICS LTD (the "Company") is a Private Limited Company, incorporated on 21 June 2012 (Thursday) in UK. The company current operating status is Active and registered office is at BIOCITY SCOTLAND, BONESS ROAD, MOTHERWELL, SCOTLAND. Visit website
BRIEF—ILC Thera gets funding to accelerate development of …
ILC Therapeutics Hybrid interferon platform technology is well positioned to address these needs and Alfacyte, our lead candidate, has the potential to become an important antiviral treatment in the ongoing global fight against COVID-19, and future pandemic threats.’’ Visit website
ILC Therapeutics announces research partnership with University …
Alfacyte™ is a drug based on a new Interferon Alpha subtype, Interferon Alpha 14, which is the most potent antiviral interferon in existence and requires very small doses for … Visit website
ILC Therapeutics raises £3.5m to advance lead interferon drug …
UK-based biotech company ILC Therapeutics has announced the successful completion of a £3.5m pre-IPO funding round. In a statement, ILC Therapeutics – which is focused on the discovery and development of a new class of interferon drugs – said it will use the funds raised to advance its lead hybrid interferon drug candidate Alfacyte. Visit website
University Of St Andrews Study Says ILC Therapeutics’ New …
The synthetic molecule Alfacyte, is a based on the human Alpha Interferons and was invented by Professor Dr William Stimson, Founder and Chief Scientific Officer at ILC Therapeutics. CEO of ILC Therapeutics, Dr Alan Walker, welcomed the results as a significant development in the fight against COVID-19. He told media,"This is a very positive ... Visit website
ILC Therapeutics Announces COVID-19 Drug Development
Alfacyte™ is a synthetic molecule based on the human Alpha Interferons and was invented by Professor William Stimson, Founder and Chief Scientific Officer at ILC Therapeutics. Dr Alan Walker, CEO of ILC Therapeutics, welcomed the results as a significant development in the fight against COVID-19: “This is a very positive development as the ... Visit website
Scottish biotech company ILC Therapeutics ... - Silicon Scotland
Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials. Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon designed to combat viral infections including Covid-19. ILC Therapeutics (ILC), a pioneer in the discovery and development of a … Visit website
Alfacyte.co.uk Login Guide
Alfacyte.co.uk Login Requirements
- Alfacyte.co.uk login page link (you can find on this page above);
- alfacyte.co.uk login correct username, password, or email if necessary;
- Internet browser, which will open the alfacyte.co.uk login page, if the page does not open, please use a VPN.
How to Login in alfacyte.co.uk? 4 Easy Steps:
- Open your browser and follow one of the official alfacyte.co.uk links above.
- On the page, find the "Login" button, usually located at the top right of the screen.
- The page will ask you to enter your alfacyte.co.uk account and password in the appropriate fields. Sometimes you will need to enter an email address instead of an account. In rare cases, the site will ask you to pass the captcha, this is done to check if you are a bot or not.
- Then press the login button, if you entered your login information correctly, you will be taken to your alfacyte.co.uk profile page. Good luck :)
Add review
